🧒 Pediatric Respiratory Considerations Neonatal & Childhood Respiratory Disorders for Medical Students

1. Neonatal Respiratory Distress: Differential & Approach

Key Concept Respiratory distress in the newborn presents with tachypnea (>60/min), grunting, nasal flaring, retractions, and cyanosis.

Condition	Timing	Key Features	Imaging
Respiratory Distress Syndrome (RDS)	Immediate (preterm)	Surfactant deficiency; ground‑glass opacities, air bronchograms, low lung volumes	Diffuse granular/ground‑glass
Transient Tachypnea of the Newborn (TTN)	First few hours	Delayed clearance of fetal lung fluid; term infants, C‑section, resolves <48h	Prominent perihilar markings, fluid in fissures
Meconium Aspiration Syndrome (MAS)	Immediate (term/post‑term)	Meconium‑stained amniotic fluid, hyperinflation, patchy infiltrates, pneumothorax risk	Coarse irregular opacities, hyperinflation
Congenital Pneumonia	Variable	GBS, E. coli, Listeria; may present with sepsis	Patchy infiltrates, effusions
Congenital Diaphragmatic Hernia (CDH)	Immediate	Scaphoid abdomen, bowel sounds in chest, respiratory distress at birth	Bowel loops in chest, mediastinal shift

Neonatal RDS (Hyaline Membrane Disease)

• Pathophysiology: Surfactant deficiency (immature type II pneumocytes) → high surface tension → atelectasis, V/Q mismatch, hypoxemia.
• Risk factors: Prematurity (inversely related to gestational age), maternal diabetes (insulin delays surfactant maturation), C‑section without labor.
• Prevention: Antenatal corticosteroids (betamethasone) to mothers at 24‑34 weeks gestation.
• Treatment: Exogenous surfactant (beractant, calfactant), CPAP, mechanical ventilation.
• Complications: Pneumothorax, intraventricular hemorrhage, bronchopulmonary dysplasia (BPD).

Bronchopulmonary Dysplasia (BPD)

• Definition: Chronic lung disease of prematurity; need for supplemental O₂ at 36 weeks postmenstrual age.
• Pathophysiology: Arrested alveolar development due to prematurity, O₂ toxicity, barotrauma, inflammation.
• Management: O₂ therapy, diuretics (furosemide), inhaled bronchodilators, systemic corticosteroids (dexamethasone for severe cases).
• Long‑term sequelae: Reactive airway disease, pulmonary hypertension, recurrent infections.

2. Pediatric Upper Airway Emergencies

Croup (Laryngotracheobronchitis)

• Etiology: Parainfluenza virus (most common). Affects children 6 months – 3 years.
• Presentation: Barky cough, inspiratory stridor, hoarseness, low‑grade fever. Worse at night.
• Imaging: Steeple sign (subglottic narrowing) on AP neck radiograph. Do not delay treatment for imaging.
• Severity (Westley Croup Score): Mild: occasional barking cough, no stridor at rest. Moderate: stridor at rest, retractions. Severe: stridor, retractions, agitation, impending respiratory failure.
• Treatment:
  • Mild: Oral dexamethasone (0.15‑0.6 mg/kg) single dose.
  • Moderate‑Severe: Nebulized racemic epinephrine + dexamethasone. Observe for 2‑4 hours after epinephrine.

Epiglottitis

• Etiology: Haemophilus influenzae type B (Hib) — now rare due to vaccination; also S. aureus, Streptococcus.
• Presentation: Abrupt onset high fever, sore throat, drooling, muffled "hot potato" voice, stridor, tripod position (leaning forward). Child appears toxic.
• Critical Warning: Do NOT examine the oropharynx, lay the patient flat, or agitate the child — may precipitate complete airway obstruction.
• Imaging: Lateral neck radiograph shows "thumbprint sign" (enlarged epiglottis). Only obtain if airway is stable and in controlled setting.
• Management: Secure airway in controlled setting (OR) — awake fiberoptic intubation or tracheostomy. IV antibiotics (ceftriaxone + vancomycin).

Foreign Body Aspiration

• Peak age: 1‑3 years. Peanuts most common.
• Presentation: Sudden choking, coughing, wheezing. May present later with recurrent pneumonia or unilateral wheeze.
• Physical exam: Unilateral decreased breath sounds, localized wheezing.
• Imaging: Inspiratory‑expiratory CXR or bilateral decubitus views → air trapping (hyperlucent lung that does not deflate on expiration). Right mainstem bronchus more common.
• Management: Rigid bronchoscopy for removal.

3. Pediatric Lower Airway Diseases

Bronchiolitis

• Etiology: Respiratory Syncytial Virus (RSV) — >70% of cases. Peak age 2‑6 months.
• Pathophysiology: Inflammation and necrosis of bronchiolar epithelium → mucus plugging, air trapping, atelectasis.
• Presentation: URI prodrome → tachypnea, wheezing, crackles, retractions, hypoxia. Apnea may occur in young infants.
• Imaging: Hyperinflation, peribronchial thickening, patchy atelectasis. Not routinely required.
• Treatment: Supportive care is mainstay.
  • Nasal suctioning, hydration, supplemental O₂ if SpO₂ <90%.
  • Do NOT use: Bronchodilators (no benefit), systemic corticosteroids (no benefit), antibiotics (unless secondary bacterial infection).
  • High‑flow nasal cannula (HFNC) or CPAP for severe cases.
• Prevention: Palivizumab (monoclonal antibody) for high‑risk infants (prematurity <29 weeks, chronic lung disease, congenital heart disease).

Pediatric Asthma

• Most common chronic disease of childhood.
• Diagnosis: Recurrent wheezing, cough, dyspnea. Spirometry often normal between exacerbations. Bronchodilator response (≥12% ↑ FEV₁) or positive methacholine challenge.
• GINA Pediatric Guidelines: Low‑dose ICS preferred controller; SABA as needed.
• Exacerbation management: Nebulized albuterol + ipratropium, systemic steroids (prednisolone or dexamethasone). Magnesium sulfate for severe cases.

4. Cystic Fibrosis (CF)

Genetics & Pathophysiology

• Autosomal recessive mutation in CFTR gene (chromosome 7). Most common: ΔF508 (deletion of phenylalanine at position 508).
• CFTR dysfunction → ↓ chloride secretion, ↑ sodium absorption → thick, viscous secretions in lungs, pancreas, GI tract, reproductive system.

Clinical Manifestations

System	Manifestations
Respiratory	Chronic cough, purulent sputum, recurrent pneumonia/bronchitis, bronchiectasis (upper lobe predominant), nasal polyps, chronic sinusitis
Gastrointestinal	Meconium ileus (newborn), pancreatic insufficiency (malabsorption, steatorrhea, failure to thrive), distal intestinal obstruction syndrome (DIOS), biliary cirrhosis
Endocrine	CF‑related diabetes (CFRD)
Reproductive	Male infertility (congenital bilateral absence of vas deferens), reduced fertility in females
Other	Clubbing, salt loss (hyponatremic dehydration), hypertrophic osteoarthropathy

Diagnosis

• Newborn screening: Elevated immunoreactive trypsinogen (IRT) → confirm with sweat chloride test.
• Sweat chloride ≥60 mmol/L (on two occasions) = diagnostic. Intermediate 30‑59 mmol/L requires CFTR genetic testing.
• Nasal potential difference measurement if sweat test equivocal.

Respiratory Microbiology in CF

• Early childhood: S. aureus, H. influenzae.
• Adolescence/Adulthood: Pseudomonas aeruginosa (mucoid strain), Burkholderia cepacia complex (poor prognosis), Stenotrophomonas, Achromobacter, Nontuberculous mycobacteria (MAC).

Management

• Airway Clearance: Chest physiotherapy, high‑frequency chest wall oscillation (vest), PEP devices, dornase alfa (Pulmozyme), hypertonic saline.
• Antibiotics: Chronic suppressive therapy (inhaled tobramycin or aztreonam for Pseudomonas). Acute exacerbations: dual IV anti‑pseudomonal antibiotics.
• Pancreatic Enzyme Replacement Therapy (PERT): Creon, Pancreaze with meals.
• Fat‑soluble vitamin supplementation (A, D, E, K).
• CFTR Modulators:
  • Ivacaftor (Kalydeco): Potentiator for gating mutations (e.g., G551D).
  • Lumacaftor/Ivacaftor (Orkambi): Corrector + Potentiator for ΔF508 homozygotes.
  • Elexacaftor/Tezacaftor/Ivacaftor (Trikafta): Highly effective modulator for patients with ≥1 ΔF508 mutation. Dramatically improves lung function and reduces exacerbations.
• Lung Transplantation: For end‑stage lung disease.

5. Congenital Lung Malformations

Lesion	Key Features	Management
Congenital Pulmonary Airway Malformation (CPAM) (formerly CCAM)	Hamartomatous lung tissue; usually single lobe. May cause respiratory distress or recurrent infection.	Surgical resection (risk of infection, malignancy)
Bronchopulmonary Sequestration	Non‑functioning lung tissue with systemic arterial supply (from aorta). Intralobar vs. extralobar.	Surgical resection or embolization of feeding vessel
Congenital Lobar Emphysema	Hyperinflation of one lobe (usually LUL) due to bronchial cartilage deficiency; air trapping.	Observation if mild; lobectomy if severe distress
Bronchogenic Cyst	Foregut duplication cyst; may compress airway or become infected.	Surgical excision

6. Pediatric Pneumonia: Age‑Specific Pathogens

Age Group	Most Common Pathogens	Empiric Therapy
Neonates (<1 month)	GBS, E. coli, Listeria, CMV	Ampicillin + Gentamicin (or Cefotaxime)
1‑3 months	Afebrile: Chlamydia trachomatis (afebrile, staccato cough), RSV. Febrile: S. pneumoniae, H. flu, S. aureus.	Afebrile: Azithromycin. Febrile: Ampicillin or Ceftriaxone.
3 months – 5 years	Viruses (RSV, parainfluenza, influenza), S. pneumoniae, H. influenzae type B (if unvaccinated)	Amoxicillin (outpatient); Ceftriaxone (inpatient)
>5 years	Mycoplasma pneumoniae, S. pneumoniae, Chlamydia pneumoniae	Azithromycin or Amoxicillin

7. Pediatric vs. Adult Anatomical & Physiological Differences

• Airway: Narrower, easily obstructed by edema or secretions. Larynx higher (C3‑4 in infant vs. C6 in adult). Epiglottis larger, omega‑shaped.
• Chest wall: More compliant → retractions more pronounced with increased work of breathing.
• Diaphragm: Primary muscle of respiration; intercostal muscles less developed. Fatigue more rapidly.
• Metabolic rate: Higher O₂ consumption → desaturate faster during apnea.
• Immune system: Immature → higher risk of severe infections.

8. Acute Respiratory Failure in Children

• More likely to progress rapidly than adults. Monitor closely for signs of impending failure: altered mental status, fatigue, paradoxical breathing, silent chest.
• Non‑invasive ventilation (BiPAP/CPAP): Effective for many pediatric respiratory failure etiologies (bronchiolitis, asthma, neuromuscular).
• Intubation considerations: Use uncuffed ETT in children <8 years (narrowest at cricoid). Cuffed ETTs increasingly used with careful pressure monitoring.
• ETT size estimation: (Age/4) + 4 (uncuffed) or (Age/4) + 3.5 (cuffed). Depth: ETT size × 3 (cm at lip).

9. Quick Reference: Pediatric Respiratory Pearls

---